Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: A phase 3 trial

Supportive Care in Cancer

Volumn 21, Issue 5, 2013, Pages 1453-1460

  Boccia, Ralph ^a   Grunberg, Steven ^b   Franco Gonzales, Edwin ^c   Rubenstein, Edward ^d   Voisin, Daniel ^e  

^a Center for Cancer and Blood Disorders   (United States)

^b Division of Hematology/Oncology   (United States)

^c Department of Endocrinology   (Mexico)

^d not available   (United States)

^e HELSINN HEALTHCARE SA   (Switzerland)

Author keywords

Chemotherapy induced nausea and vomiting; Moderately emetogenic chemotherapy; Palonosetron

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; OXALIPLATIN; PALONOSETRON; PLACEBO;

ADULT; ARTICLE; BLOOD CHEMISTRY; BREAST CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON CANCER; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HEMATOLOGICAL PARAMETERS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84879689373     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1691-5     Document Type: Article

References (9)

1. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 89:645-655
2. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
3. Navari RM (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2:591-602
4. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482
5. Gralla R, Lichinitser M, Van DV, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
6. Rojas C, Slusher B (2012) Pharmacological mechanisms of 5-HT3 and tachykinin NK1 recptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684:1-7
7. Basch E, Prestrud A, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2006) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189-4198. doi: 10.1200/JCO.2010.34.4614
8. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
9. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba S (2012) Antiemesis. J Natl Compr Canc Netw 10:456-485